In conclusion, by combing transcriptomic and MR analysis, we provided the evidence that PLAUR, as an SRG, may play a role in the development of AD, which may provide the rationale of existing drugs or novel drugs for AD, such as LENOGRASTIM and RUXOLITINIB (Cannon et al., 2024). This evidence concerns the gene PLAUR and Alzheimer disease.